论文部分内容阅读
目的:探讨奈达铂联合紫杉醇注射液对卵巢癌术后患者ROMA指数、HE4水平的影响及临床疗效。方法:选取我院收治的卵巢癌术后患者70例,随机分为实验组和对照组,每组35例。对照组采用紫杉醇注射液治疗;实验组在对照组基础上联合奈达铂注射液治疗。观察并比较治疗前后两组患者ROMA指数、血清CA125和HE4水平、生存期、临床疗效及不良反应情况。结果:与治疗前相比,治疗后两组患者ROMA指数、血清CA125及HE4水平均下降,差异具有统计学意义(P<0.05);与对照组比较,实验组患者治疗后ROMA指数、血清HE4及CA125水平较低,差异具有统计学意义(P<0.05);与对照组比较,实验组患者生存期明显延长,差异具有统计学意义(P<0.05)。结论:奈达铂联合紫杉醇注射液治疗卵巢癌具有显著的临床疗效,能够降低ROMA指数和血清CA125、HE4水平,而且毒副作用较小,可在临床进一步推广应用。
Objective: To investigate the effect of nedaplatin plus paclitaxel injection on ROMA index and HE4 level in postoperative patients with ovarian cancer and its clinical efficacy. Methods: Seventy patients with postoperative ovarian cancer admitted to our hospital were randomly divided into experimental group and control group with 35 cases in each group. The control group was treated with paclitaxel injection. The experimental group was treated with nedaplatin injection on the basis of the control group. ROMA index, serum CA125 and HE4 levels, survival, clinical efficacy and adverse reactions were observed and compared between the two groups before and after treatment. Results: The ROMA index, serum CA125 and HE4 levels of two groups decreased after treatment compared with those before treatment, the difference was statistically significant (P <0.05). Compared with the control group, ROMA index, serum HE4 (P <0.05). Compared with the control group, the survival time of experimental group was significantly longer, the difference was statistically significant (P <0.05). Conclusion: Nedaplatin combined with paclitaxel injection has significant clinical curative effect on ovarian cancer, can reduce ROMA index and serum CA125, HE4 levels, and the side effects are small and can be further popularized and applied in clinic.